All results

8 results for randomized double blind placebo controlled parallel group multicenter study safety

• Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)

  This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing…

  Ages

  18 Years - N/A

  Sexes

  All

• Edgewise-210

  The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a…

  Ages

  4 Years - 9 Years

  Sexes

  Male

• IMPALA-2

  160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for…

  Ages

  18 Years - N/A

  Sexes

  All

• United therapeutics 301

  Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of…

  Ages

  18 Years - N/A

  Sexes

  All

• ReCePI

  The objective of this study is to evaluate the efficacy and safety of RBC transfusion for support of acute anemia in cardiovascular surgery patients based on…

  Ages

  11 Years - N/A

  Sexes

  All

• GCAptAIN

  This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell…

  Ages

  50 Years - N/A

  Sexes

  All

• Soleno C602

  This is a multi-center, multi-period study with an open-label period followed by a double-blind, placebo-controlled, randomized withdrawal period evaluating…

  Ages

  4 Years - N/A

  Sexes

  All

• REMODEL II

  To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis The study CLOU064C12302 consists of an…

  Ages

  18 Years - 55 Years

  Sexes

  All